Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis

Bone

Volumn 71, Issue , 2015, Pages 217-226

  Kameda, Yusuke ^a   Takahata, Masahiko ^a   Mikuni, Shintaro ^b   Shimizu, Tomohiro ^a   Hamano, Hiroki ^a   Angata, Takashi ^c   Hatakeyama, Shigetsugu ^a   Kinjo, Masataka ^b   Iwasaki, Norimasa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

Author keywords

DAP12; Menopause; Osteoclast; Osteoporosis; Sialic acid; Siglec 15

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; FC RECEPTOR; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 15; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ESTROGEN; IMMUNOGLOBULIN; LIGAND; MEMBRANE PROTEIN; SIGLEC-15 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TYROBP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSKELETON; DISEASE RESISTANCE; ESTROGEN DEFICIENCY; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BONE DEVELOPMENT; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; HUMAN; INTRACELLULAR SPACE; METABOLISM; MOLECULARLY TARGETED THERAPY; OSTEOBLAST; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE RESORPTION; CYTOSKELETON; ESTROGENS; FEMALE; HUMANS; IMMUNOGLOBULINS; INTRACELLULAR SPACE; LIGANDS; MEMBRANE PROTEINS; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RECEPTORS, IGG; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84912028359     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.10.027     Document Type: Article

References (33)

1. Kaifu T., Nakahara J., Inui M., Mishima K., Momiyama T., Kaji M., et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003, 111:323-332.
2. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
3. Humphrey M.B., Ogasawara K., Yao W., Spusta S.C., Daws M.R., Lane N.E., et al. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J Bone Miner Res 2004, 19:224-234.
4. Mocsai A., Humphrey M.B., Van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004, 101:6158-6163.
5. Ishida-Kitagawa N., Tanaka K., Bao X., Kimura T., Miura T., Kitaoka Y., et al. Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12kDa (DAP12). J Biol Chem 2012, 287:17493-17502.
6. Humphrey M.B., Daws M.R., Spusta S.C., Niemi E.C., Torchia J.A., Lanier L.L., et al. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res 2006, 21:237-245.
7. Dietrich J., Cella M., Seiffert M., Buhring H.J., Colonna M. Cutting edge: signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. J Immunol 2000, 164:9-12.
8. Bakker A.B., Baker E., Sutherland G.R., Phillips J.H., Lanier L.L. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci U S A 1999, 96:9792-9796.
9. Klesney-Tait J., Turnbull I.R., Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006, 7:1266-1273.
10. Joyce-Shaikh B., Bigler M.E., Chao C.C., Murphy E.E., Blumenschein W.M., Adamopoulos I.E., et al. Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. J Exp Med 2010, 207:579-589.
11. Kameda Y., Takahata M., Komatsu M., Mikuni S., Hatakeyama S., Shimizu T., et al. Siglec-15 regulates ssteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling adaptor DAP12. J Bone Miner Res 2013, 28:2463-2475.
12. Stuible M., Moraitis A., Fortin A., Saragosa S., Kalbakji A., Filion M., et al. Mechanism and Function of Monoclonal Antibodies Targeting Siglec-15 for Therapeutic Inhibition of Osteoclastic Bone Resorption. J Biol Chem 2014, 289:6498-6512.
13. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001, 98:13960-13965.
14. Kimble R.B., Bain S., Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 1997, 12:935-941.
15. Ammann P., Rizzoli R., Bonjour J.P., Bourrin S., Meyer J.M., Vassalli P., et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997, 99:1699-1703.
16. Fuller K., Murphy C., Kirstein B., Fox S.W., Chambers T.J. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002, 143:1108-1118.
17. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000, 275:4858-4864.
18. Angata T., Tabuchi Y., Nakamura K., Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 2007, 17:838-846.
19. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
20. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:2-17.
21. Takeshita S., Kaji K., Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000, 15:1477-1488.
22. Kaneda T., Nojima T., Nakagawa M., Ogasawara A., Kaneko H., Sato T., et al. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. J Immunol 2000, 165:4254-4263.
23. Takahata M., Iwasaki N., Nakagawa H., Abe Y., Watanabe T., Ito M., et al. Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone 2007, 41:77-86.
24. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000, 106:1229-1237.
25. Barrow A.D., Raynal N., Andersen T.L., Slatter D.A., Bihan D., Pugh N., et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest 2011, 121:3505-3516.
26. Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int J Med Sci 2012, 9:825-832.
27. Hiruma Y, Tsuda E, Maeda N, Okada A, Kabasawa N, Miyamoto M, et al. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice. Bone 53: 87-93.
28. Zou W., Zhu T., Craft C.S., Broekelmann T.J., Mecham R.P., Teitelbaum S.L. Cytoskeletal dysfunction dominates in DAP12-deficient osteoclasts. J Cell Sci 2010, 123:2955-2963.
29. Wu Y., Torchia J., Yao W., Lane N.E., Lanier L.L., Nakamura M.C., et al. Bone microenvironment specific roles of ITAM adapter signaling during bone remodeling induced by acute estrogen-deficiency. PLoS One 2007, 2:e586.
30. Turnbull I.R., Colonna M. Activating and inhibitory functions of DAP12. Nat Rev Immunol 2007, 7:155-161.
31. Hamerman J.A., Tchao N.K., Lowell C.A., Lanier L.L. Enhanced toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 2005, 6:579-586.
32. Turnbull I.R., Gilfillan S., Cella M., Aoshi T., Miller M., Piccio L., et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 2006, 177:3520-3524.
33. Hamerman J.A., Jarjoura J.R., Humphrey M.B., Nakamura M.C., Seaman W.E., Lanier L.L. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 2006, 177:2051-2055.